Christopher Richard Anzalone - 03 May 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
03 May 2023
Net transactions value
-$3,914,768
Form type
4
Filing time
05 May 2023, 19:04:35 UTC
Previous filing
20 Dec 2022
Next filing
20 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Options Exercise $110,405 +54,928 +1.5% $2.01* 3,816,266 03 May 2023 Direct F1
transaction ARWR Common Stock Sale $2,149,882 -54,928 -1.4% $39.14 3,761,338 03 May 2023 Direct F2
transaction ARWR Common Stock Options Exercise $100,500 +50,000 +1.3% $2.01* 3,811,338 04 May 2023 Direct F1
transaction ARWR Common Stock Sale $935,592 -24,008 -0.63% $38.97 3,787,330 04 May 2023 Direct F3
transaction ARWR Common Stock Sale $1,040,200 -25,992 -0.69% $40.02 3,761,338 04 May 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Stock Option (right to buy) Options Exercise $0 -54,928 -9.6% $0.000000 516,980 03 May 2023 Common Stock 54,928 $2.01 Direct F5, F6
transaction ARWR Stock Option (right to buy) Options Exercise $0 -50,000 -9.7% $0.000000 466,980 04 May 2023 Common Stock 50,000 $2.01 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired through exercise of options expiring 5/6/23. See Table II.
F2 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.47 to $39.47, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $40.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5 Represents first vesting date. Option vested over four years from date of grant.
F6 Represents total stock options beneficially owned at various strike prices.